Ad-H4, rH4, the hetrologous prime boost combination, non-vaccinated, and BCG vaccinated mice were included.
In contrast, the heterologous prime boost combination resulted in augmentation of both the CD4 and CD8 response.
We clearly show that rH4/CAF01 induces primarily CD4 T cells, and Ad-H4 CD8 T cells, but the heterologous prime boost combination induces both CD4 and CD8 T cells.
The other track of malaria vaccine development is genetic vaccination with DNA plasmids, recombinant viral vectors, or often with both in a DNA prime-viral boost combination.
Thus, mice vaccinated with the heterologous prime boost combination of rH4/Ad-H4 showed a bacterial reduction of 1.2 Log10±0.1 CFU, which was significantly higher than the protection in Ad-H4 and rH4 vaccinated mice (p<0.01 and p<0.001, respectively).
Currently, a focused Phase II study is evaluating the VRC HIV-1 DNA prime - rAd5 boost combination for its effect on early control of viral load in those study participants who become HIV-1 infected.
In the present study we therefore compared the well characterized vaccine fusion molecule rH4 (Ag85B-TB10.4) delivered either as a subunit vaccine in cationic liposomes (rH4/CAF01) expressed in an adeno5 vector (ad-H4) or as a heterologous prime boost combination.
As we had observed an increase in both CD4 and CD8 T cells in the group receiving the heterologous prime boost combination of rH4/Ad-H4, and increased protection, it was important to compare how the vaccine primed CD4/CD8 T cells responded to an M.tb infection (in the group where they were both induced, e.g. the rH4/Ad-H4 group).
Our results suggest that the constructed chimeric multi-epitope DNA has potential for a candidate vaccine against ALV-J when used in proper prime-boost combinations.
We tested select heterologous prime-boost combinations and identified recombinant vesicular stomatitis virus (rVSV) and recombinant Venezuelan equine encephalitis virus replicons (VRP) as the most synergistic regimen.
Thus, while novel vectors and heterologous prime-boost combinations are getting better at inducing higher frequencies of HIV-1-specific T cells, less attention has been paid to how these vaccines can elicit T cells capable of recognizing multiple HIV-1 variants.
